Page 35 - Read Online

Llamoza-Torres et al. Metab Target Organ Damage 2024;4:40 https://dx.doi.org/10.20517/mtod.2024.64 Page 15 of 18

fatty liver disease: a meta-analysis and review of current literature. HPB 2021;23:1164-74. DOI PubMed
51. Lin YP, Lin SH, Wang CC, et al. Impact of MAFLD on HBV-related stage 0/a hepatocellular carcinoma after curative resection. J
Pers Med 2021;11:684. DOI PubMed PMC
52. Wong RJ, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Improved survival outcomes in patients with non-alcoholic
steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United network for organ sharing
data. Clin Transplant 2014;28:713-21. DOI PubMed
53. Haldar D, Kern B, Hodson J, et al; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation
for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol 2019;71:313-22. DOI PubMed PMC
54. Zamora-Olaya JM, Tejero-Jurado R, Alañón-Martínez PE, et al. Donor atheromatous disease is a risk factor for hepatic artery
thrombosis after liver transplantation. Clin Transplant 2024;38:e15405. DOI PubMed
55. Holzner ML, Florman S, Schwartz ME, Tabrizian P. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated
hepatocellular carcinoma. HPB 2022;24:470-7. DOI PubMed
56. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis
have lower risk hepatocellular carcinoma. Liver Transpl 2017;23:1015-22. DOI PubMed
57. Hernandez-Alejandro R, Croome KP, Drage M, et al. A comparison of survival and pathologic features of non-alcoholic
steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol 2012;18:4145-9. DOI PubMed
PMC
58. Kern B, Feurstein B, Fritz J, et al. High incidence of hepatocellular carcinoma and postoperative complications in patients with
nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. Eur J Gastroenterol Hepatol 2019;31:205-10.
DOI PubMed
59. Sadler EM, Mehta N, Bhat M, et al. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of
hepatocellular carcinoma. Transplantation 2018;102:640-7. DOI PubMed
60. Young S, Sanghvi T, Rubin N, et al. Transarterial chemoembolization of hepatocellular carcinoma: propensity score matching study
comparing survival and complications in patients with nonalcoholic steatohepatitis versus other causes cirrhosis. Cardiovasc
Intervent Radiol 2020;43:65-75. DOI PubMed
61. Schotten C, Bechmann LP, Manka P, et al. NAFLD-associated comorbidities in advanced stage HCC do not alter the safety and
efficacy of yttrium-90 radioembolization. Liver Cancer 2019;8:491-504. DOI PubMed PMC
62. Brunson C, Struycken L, Schaub D, et al. Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic
steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis. Abdom Radiol 2024;49:2714-25. DOI
PubMed PMC
63. Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol 2023;79:506-15. DOI
PubMed
64. Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J
Clin Oncol 2024;42:1830-50. DOI PubMed
65. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to
hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-6. DOI PubMed
66. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients
with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 2018;155:443-57.e17. DOI PubMed
67. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or
cirrhosis: an international collaborative study. Hepatology 2011;54:1208-16. DOI PubMed PMC
68. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33
years of follow-up. Hepatology 2015;61:1547-54. DOI PubMed
69. Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver
disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol 2022;20:283-92.e10. DOI PubMed
70. Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 2021;75:1476-84. DOI PubMed
71. Behari J, Gougol A, Wang R, et al. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or
advanced liver fibrosis. Hepatol Commun 2023;7:e00183. DOI PubMed PMC
72. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic
steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e1-9.
DOI PubMed PMC
73. Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated
nonalcoholic steatohepatitis. Liver Int 2021;41:982-95. DOI PubMed
74. Le P, Payne JY, Zhang L, et al. Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-
analysis of paired biopsy or imaging studies. Clin Gastroenterol Hepatol 2023;21:1154-68. DOI PubMed PMC
75. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an
exponential increase in burden of disease. Hepatology 2018;67:123-33. DOI PubMed PMC
76. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States
and Europe. Hepatology 2016;64:1577-86. DOI PubMed
77. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on